Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)

Shirakawa, T; Shimokawa, M; Otsuka, T; Shinohara, Y; Toyodome, K; Kusano, W; Nakazawa, J; Kodama, T; Kawahira, M; Shimokawa, H; Koike, T; Koga, F; Yunotani, S; Nakashita, S; Oza, N; Noge, S; Murayama, K; Oda, H; Mitsui, N; Kawasaki, R; Morikita, T; Takeshita, S; Arima, S; Shibata, R; Kakihara, A; Yoshihiro, T; Imajima, T; Yamaga, S; Arita, S; Kawaguchi, Y; Nishikawa, K; Inagaki, T; Otsu, S; Taguchi, H; Jikuya, K; Terada, T; Sakai, T; Ueda, Y; Sakae, T; Sawase, H; Kawahira, M; Nio, K; Araki, N; Sakai, K; Ide, Y; Shibuki, T; Miwa, K; Kubotsu, Y; 細川, 歩; ホソカワ, アユム; Hosokawa, Ayumu; Komori, A; Honda, T; Tsuneyoshi, K; Fujita, T; Mizuta, T; Mitsugi, K

doi:https://doi.org/10.1016/j.esmogo.2025.100150

WEKO3

lat lon distance

[[sub_check.contents]]

[[sub_radio.contents]]

Field does not validate

[[sub_attr.contents]]　

インデックスツリー

アイテム

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)

http://hdl.handle.net/10458/0002002292

名前 / ファイル	ライセンス	アクション
Fulltext (725 KB)

アイテムタイプ

学術雑誌論文 / Journal Article(1)

公開日

2026-02-09

タイトル

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)

言語

eng

キーワード

言語

キーワード

chemotherapy

キーワード

言語

キーワード

nanoliposomal irinotecan

キーワード

言語

キーワード

pancreatic cancer

キーワード

言語

キーワード

prospective

キーワード

言語

キーワード

real-world data

資源タイプ

journal article

アクセス権

open access

著者

Shirakawa, T

Shimokawa, M
Otsuka, T
Shinohara, Y

Toyodome, K
Kusano, W
Nakazawa, J
Kodama, T
Kawahira, M
Shimokawa, H

Koike, T

Koga, F
Yunotani, S
Nakashita, S
Oza, N
Noge, S
Murayama, K
Oda, H
Mitsui, N
Kawasaki, R
Morikita, T
Takeshita, S
Arima, S
Shibata, R
Kakihara, A
Yoshihiro, T
Imajima, T
Yamaga, S
Arita, S
Kawaguchi, Y
Nishikawa, K
Inagaki, T
Otsu, S
Taguchi, H
Jikuya, K
Terada, T
Sakai, T
Ueda, Y
Sakae, T
Sawase, H
Kawahira, M
Nio, K
Araki, N
Sakai, K
Ide, Y
Shibuki, T
Miwa, K
Kubotsu, Y
細川, 歩

WEKO 33635
e-Rad_Researcher 90432111

ja	細川, 歩宮崎大学
ja-Kana	ホソカワ, アユム
en	Hosokawa, Ayumu University of Miyazaki

Search repository

Komori, A
Honda, T
Tsuneyoshi, K
Fujita, T
Mizuta, T
Mitsugi, K

抄録

内容記述タイプ

Abstract

内容記述

Background
Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second- or later-line regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer (urPC). However, limited prospective clinical data on the efficacy and safety of NFF in a real-world setting have been presented. Therefore, we conducted this observational, real-world study to investigate the efficacy and safety of NFF.
Patients and methods
We collected prospective data of urPC patients treated with NFF in 17 hospitals in Japan from 2021 to 2023. The primary endpoint was overall survival (OS). Secondary endpoints were overall response rate, disease control rate, progression-free survival, dose intensity, and adverse events (AEs).
Results
NFF was administered to 150 patients with a mean age of 72 years. The median follow-up period was 7.2 months. All patients had previously received gemcitabine-based therapy. The median OS was 7.8 months; median progression-free survival was 3.7 months; median overall response rate was 11%; and median disease control rate was 56%. Median relative dose intensity was 72.7% with nanoliposomal irinotecan and 79.4% with fluorouracil. Grade 3/4 hematological and nonhematological AEs occurred in 52 and 70 patients, respectively. Neutropenia (28%) and anorexia (19%) were common grade 3/4 AEs. Subanalysis of patients with second-line and third- or later-line therapy demonstrated no significant difference in OS (7.4 versus 7.8 months, respectively; P = 0.88). Integrated analysis of the prospective and retrospective phases of the study showed that median OS was 8.0 months.
Conclusions
NFF has an appropriate efficacy and safety profile and is a candidate for second- or later-line therapy for urPC.

言語

書誌情報

en : ESMO gastrointestinal oncology

巻 8, p. 100150, 発行日 2025-06

出版者

Elsevier BV

言語

ISSN

収録物識別子タイプ

EISSN

収録物識別子

29498198

DOI

Versions

Ver.1

2026-02-09 08:12:32.039268

Show All versions

Cite as

Other

エクスポート

OAI-PMH

JPCOAR 2.0
JPCOAR 1.0
DublinCore
DDI

Other Formats

メニューを最小化

インデックスリンク

インデックスツリー

アイテム

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)

× Shirakawa, T

× Shimokawa, M

× Otsuka, T

× Shinohara, Y

× Toyodome, K

× Kusano, W

× Nakazawa, J

× Kodama, T

× Kawahira, M

× Shimokawa, H

× Koike, T

× Koga, F

× Yunotani, S

× Nakashita, S

× Oza, N

× Noge, S

× Murayama, K

× Oda, H

× Mitsui, N

× Kawasaki, R

× Morikita, T

× Takeshita, S

× Arima, S

× Shibata, R

× Kakihara, A

× Yoshihiro, T

× Imajima, T

× Yamaga, S

× Arita, S

× Kawaguchi, Y

× Nishikawa, K

× Inagaki, T

× Otsu, S

× Taguchi, H

× Jikuya, K

× Terada, T

× Sakai, T

× Ueda, Y

× Sakae, T

× Sawase, H

× Kawahira, M

× Nio, K

× Araki, N

× Sakai, K

× Ide, Y

× Shibuki, T

× Miwa, K

× Kubotsu, Y

× 細川, 歩

× Komori, A

× Honda, T

× Tsuneyoshi, K

× Fujita, T

× Mizuta, T

× Mitsugi, K

Versions

Share

Cite as

Other

エクスポート

コミュニティ